209 related articles for article (PubMed ID: 19833757)
1. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.
Petri M; Singh S; Tesfasyone H; Malik A
J Rheumatol; 2009 Nov; 36(11):2476-80. PubMed ID: 19833757
[TBL] [Abstract][Full Text] [Related]
2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
3. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
[TBL] [Abstract][Full Text] [Related]
4. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
Ng KP; Manson JJ; Rahman A; Isenberg DA
Arthritis Rheum; 2006 Dec; 55(6):900-4. PubMed ID: 17139667
[TBL] [Abstract][Full Text] [Related]
5. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?
Esdaile JM; Joseph L; Abrahamowicz M; Li Y; Danoff D; Clarke AE
J Rheumatol; 1996 Nov; 23(11):1891-6. PubMed ID: 8923362
[TBL] [Abstract][Full Text] [Related]
6. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study.
Zonana-Nacach A; Salas M; Sánchez ML; Camargo-Coronel A; Bravo-Gatica C; Mintz G
J Rheumatol; 1995 Jan; 22(1):45-9. PubMed ID: 7699680
[TBL] [Abstract][Full Text] [Related]
7. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
8. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population.
Jonsson H; Nived O; Sturfelt G
Medicine (Baltimore); 1989 May; 68(3):141-50. PubMed ID: 2785628
[TBL] [Abstract][Full Text] [Related]
9. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
Ho A; Magder LS; Barr SG; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
[TBL] [Abstract][Full Text] [Related]
10. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
Ho A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
[TBL] [Abstract][Full Text] [Related]
11. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).
Merrill J; Buyon J; Furie R; Latinis K; Gordon C; Hsieh HJ; Brunetta P
Lupus; 2011 Jun; 20(7):709-16. PubMed ID: 21478286
[TBL] [Abstract][Full Text] [Related]
12. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with active systemic lupus erythematosus after endstage renal disease.
Szeto CC; Li PK; Wong TY; Leung CB; Lui SF
J Rheumatol; 1998 Aug; 25(8):1520-5. PubMed ID: 9712094
[TBL] [Abstract][Full Text] [Related]
14. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
15. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
16. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
[TBL] [Abstract][Full Text] [Related]
17. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
J Rheumatol; 2010 Mar; 37(3):568-73. PubMed ID: 20110519
[TBL] [Abstract][Full Text] [Related]
18. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
19. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
20. Flares in pediatric systemic lupus erythematosus.
Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
